Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Topical Betaxolol for the Prevention of Retinopathy of Prematurity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01660620
Recruitment Status : Completed
First Posted : August 8, 2012
Last Update Posted : January 3, 2013
Ohio State University
University of Minnesota
University of Oklahoma
The University of Texas Health Science Center, Houston
Information provided by (Responsible Party):
William V Good, MD, Smith-Kettlewell Eye Research Institute

Brief Summary:
We hypothesize that topical betaxolol will reduce the development of severe retinopathy of prematurity.

Condition or disease Intervention/treatment Phase
Development of Side Effects From Betaxolol Drug: Betaxolol Drug: topical betaxolol Phase 1

Detailed Description:
The drug is administered twice a day between 32 and 35 weeks gestational age, at a t ime when ROP is most likely to arise.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Topical Betaxolol for the Prevention of Retinopathy of Prematurity
Study Start Date : April 2011
Actual Primary Completion Date : November 2011
Actual Study Completion Date : November 2011

Resource links provided by the National Library of Medicine

Drug Information available for: Betaxolol

Arm Intervention/treatment
Experimental: betaxolol
betaxolol 0.25% 2 per day for 3 weeks
Drug: Betaxolol
Placebo Comparator: placebo
masked labeling also 2 per day administration
Drug: topical betaxolol
given topically

Primary Outcome Measures :
  1. development of apnea and or bradycardia [ Time Frame: 3 weeks ]
    babies were monitored and HR/RR monitored and recorded by masked observers, periodically

Secondary Outcome Measures :
  1. development of ROP requiring treatment [ Time Frame: 7 weeks ]
    Type I ROP was used as a secondary outcome measure

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   32 Weeks to 32 Weeks   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • <1251 grms birth weight

Exclusion Criteria:

  • ocular defect

Layout table for additonal information
Responsible Party: William V Good, MD, Administrator, Smith-Kettlewell Eye Research Institute Identifier: NCT01660620    
Other Study ID Numbers: 108298
First Posted: August 8, 2012    Key Record Dates
Last Update Posted: January 3, 2013
Last Verified: August 2012
Keywords provided by William V Good, MD, Smith-Kettlewell Eye Research Institute:
betaxolol/ retinopathy of prematurity
Additional relevant MeSH terms:
Layout table for MeSH terms
Retinal Diseases
Retinopathy of Prematurity
Premature Birth
Eye Diseases
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications
Infant, Premature, Diseases
Infant, Newborn, Diseases
Antihypertensive Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action